33469-13-5

Basic information

• Product Name: 1H-IMidazole, 2-(2-chlorophenyl)-5-(trifluoroMethyl)-
• Synonyms: 1H-IMidazole, 2-(2-chlorophenyl)-5-(trifluoroMethyl)-;2-(2-chlorophenyl)-5-(trifluoromethyl)-1H-Imidazole
• CAS NO: 33469-13-5
• Molecular Formula: C₁₀H₆ClF₃N₂
• Molecular Weight: 246.6162496
• Mol File: 33469-13-5.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-IMidazole, 2-(2-chlorophenyl)-5-(trifluoroMethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-IMidazole, 2-(2-chlorophenyl)-5-(trifluoroMethyl)-(33469-13-5)
• EPA Substance Registry System: 1H-IMidazole, 2-(2-chlorophenyl)-5-(trifluoroMethyl)-(33469-13-5)

Safety Data

• Hazardous Substances Data: 33469-13-5(Hazardous Substances Data)

Usage

General Description

1H-Imidazole, 2-(2-chlorophenyl)-5-(trifluoromethyl)- is a chemical compound with the molecular formula C10H7ClF3N2. It is a derivative of imidazole and is characterized by the presence of a chlorophenyl group and a trifluoromethyl group. 1H-IMidazole, 2-(2-chlorophenyl)-5-(trifluoroMethyl)- has applications in the field of organic synthesis and pharmaceuticals, where it is used as a building block for the synthesis of various pharmaceuticals and agrochemicals. It can also act as a ligand in coordination chemistry and serve as a precursor in the production of various other chemical compounds. Additionally, it may have potential biological activity and may be used in medicinal research.

Upstream product

• 89-98-5 2-chloro-benzaldehyde 
• 431-67-4 1,1-dibromo-3,3,3-trifluoroacetone 
• 91944-47-7 3,3,3-Trifluoropyruvaldehyde 

Downstream Products

• 279251-14-8 2-(2-chlorophenyl)-1H-4-imidazolcarbaldehyde 
• 279250-96-3 2-(2-chlorophenyl)-4-cyano-1H-imidazole 

Relevant articles and documents

Liver X Receptor (LXR) partial agonists: Biaryl pyrazoles and imidazoles displaying a preference for LXRβ

A series of biaryl pyrazole and imidazole Liver X Receptor (LXR) partial agonists has been synthesized displaying LXRβ selectivity. The LXRβ selective partial agonist 18 was identified with potent induction of ATP binding transporters ABCA1 and ABCG1 in human whole blood (EC50 = 1.2 μM, 55% efficacy). In mice 18 displayed peripheral induction of ABCA1 at 3 and 10 mpk doses with no significant elevation of plasma or hepatic triglycerides at these doses, showing an improved profile compared to a full pan-agonist.

Trifluoromethylimidazoles and a method for their preparation

4(5)-Trifluoromethylimidazoles having optional substituents in the 1 and 2 positions are provided. The novel 4(5)-trifluoromethylimidazoles are prepared by reacting a 1,1-dihalo-3,3,3-trifluoroacetone compound with an appropriate carboxaldehyde and ammoni

4-Trifluoromethylimidazoles and 5-(4-pyridyl)-1,2,4-triazoles, new classes of xanthine oxidase inhibitors.

The syntheses of a number of 2-substituted 4-trifluoromethylimidazoles and 3-substituted 5-(4-pyridyl)-1,2,4-triazoles are described. The trifluoromethylimidazoles were prepared from 3,3-dibromo-1,1,1-trifluoroacetone after hydrolysis with aqueous sodium acetate solution and condensation with an aldehyde in the presence of ammonia. Basic hydrolysis of the trifluoromethyl group was found to provide a facile method for the synthesis of imidazole-4-carboxylic acids. In the imidazole series a 2-aryl substituent and a free imino group were required for xanthine oxidase inhibitory activity. The triazoles were obtained through the reaction of an aroylhydrazine and an imino ether followed by thermal ring closure of the intermediate acylamidrazone. As in the imidazole series, a free imino group is an absolute requirement for in vitro activity. Additional structure-activity relationships of these compounds are presented.